未登录

S

Susan Hutchinson

Eli Lilly

H指数:22

被引数:2,526

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unmet treatment needs in migraine: Results of the OVERCOME (US) study

偏头痛中的未满足治疗需求：OVERCOME（美国）研究的结果

IF4

2026-02-010

OAAI

Opioid Use among People with Migraine: Results of the OVERCOME (US) Study

偏头痛患者中的阿片类药物使用：OVERCOME (US) 研究结果

Pain and Therapy

IF3.3

2025-09-190

OAAI

Development of the Migraine-Related Stigma (MiRS) Questionnaire: Results of the OVERCOME (US) Study

IF4

2025-01-220

OA

Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study

IF4

2024-05-240

OAAI

Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life Results of the OVERCOME (US) Study

IF8.5

2024-02-1317

OAAI

Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis

乌布罗格普特急性治疗月经前偏头痛发作的安全性和有效性: 事后分析

IF4

2023-09-014

OAAI

Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial

每日一次口服atogepant用于偏头痛的长期预防性治疗: 一项多中心，随机，开放标签，3期试验的结果

IF4

2023-01-1831

OAAI

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States (May, 10.1007/s12325-021-01781-z, 2021)

ADVANCES IN THERAPY

IF4

2021-09-130

OA

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

估计美国偏头痛新急性治疗合格患者人群的框架

ADVANCES IN THERAPY

IF4

2021-05-317

OAAI

Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II

在两项单次发作的3期随机试验中，ubrogepant在具有主要心血管危险因素的参与者中的安全性和有效性: 实现I和II

IF4.6

2021-04-1923

PREAI

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis

IF4

2021-03-2220

OAAI

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials

NEUROLOGY AND THERAPY

IF4.8

2021-02-2013

OAAI

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials

ADVANCES IN THERAPY

IF4

2021-02-0510

OAAI

Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study

急性处方偏头痛药物使用的特征: 来自CaMEO研究的结果

MAYO CLINIC PROCEEDINGS

IF6.7

2020-04-0118

OAAI

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial

乌布罗格普特用于偏头痛急性治疗的长期安全性评估: 3期，随机，52周扩展试验

IF4

2020-01-0879

OAAI

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

IF4

2019-09-2241

OAAI

Use of Common Migraine Treatments in Breast-Feeding Women: A Summary of Recommendations

在哺乳期妇女中使用常见的偏头痛治疗方法: 建议摘要

IF4

2013-03-0634

OAAI

TEACHING CASE: MENOPAUSAL MIGRAINE

IF4

2010-01-241

PREAI

Childhood Maltreatment and Migraine (Part II). Emotional Abuse as a Risk Factor for Headache Chronification

IF4

2010-01-04111

OAAI

Childhood Maltreatment and Migraine (Part I). Prevalence and Adult Revictimization: A Multicenter Headache Clinic Survey

IF4

2010-01-04162

PREAI